Login to Your Account

Smarticles Extend Their Reach in ProNAi's DNAi Approach

By Marie Powers
Staff Writer

Thursday, March 15, 2012

ProNAi Therapeutics Inc. became the second biotech to validate a savvy technology purchase by Marina Biotech Inc., extending its license for Marina's "Smarticles" liposomal delivery technology – used in its nucleic acid-based DNA interference (DNAi) therapies – from the clinic to potential commercialization.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription